Recurrent Melanoma Completed Phase 1 Trials for Temsirolimus (DB06287)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00112476Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid TumorsTreatment
NCT00349206Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable MelanomaTreatment